Due to the limited height of commercial prone breast boards, large or pendulous breasts may contact the base layer of the board during simulation and throughout the course of treatment. Our clinic has historically identified and marked this region of contact to ensure reproducible setup. However, this situation may result in unwanted hotspots where the breast rests atop the board due to electron scatter. In this study, we performed in‐vivo dosimetric measurements to evaluate the surface dose in regions of contact with the immobilization device. The average dose and hotspot were identified and evaluated to determine whether plan modifications were necessary to avoid excess skin toxicity at the skin/breast board interface. The film method results were validated against a commissioned in vivo OSLD dosimetry system. Radiochromic film measurements agreed with OSLD readings (n = 18) overall within 1%, σ = 6.4%, with one deviation of >10%. Pertinent information for the physician includes the average, maximum, and minimum doses received at the film interface. Future readings will not require OSLD verification. Physicians now have access to additional spatial data to correlate skin toxicity with doses delivered at the skin/breast board interface. This new technique is now an established procedure at our clinic, and can inform future efforts to model enhanced methods to calculate the dosimetric effects from the prone breast board in the treatment planning system.

中文翻译：

---

开发用于俯卧的胸板/皮肤界面的剂量验证的体内技术

由于商业俯卧胸板的高度有限，因此在模拟过程中以及在整个治疗过程中，大的或下垂的乳房可能会接触到胸板的基础层。我们的诊所历史上已经确定并标记了此接触区域，以确保可重复设置。但是，这种情况可能会导致不必要的热点，由于电子散射，乳房会停在板上。在这项研究中，我们进行了体内剂量测定，以评估与固定装置接触区域的表面剂量。确定并评估平均剂量和热点，以确定是否有必要修改计划，以避免在皮肤/乳房板界面产生过多的皮肤毒性。胶片方法的结果已针对体内委托进行了验证OSLD剂量测定系统。放射致变色膜的测量结果与OSLD读数（n = 18）一致，总误差在1％以内，σ= 6.4％，偏差大于10％。医师的相关信息包括在胶片界面处接收的平均，最大和最小剂量。将来的读数将不需要OSLD验证。医师现在可以访问其他空间数据，以将皮肤毒性与在皮肤/乳房板界面处传递的剂量相关联。现在，这项新技术已成为我们诊所的既定程序，可以为将来的工作提供参考，以建模增强方法，以在治疗计划系统中计算俯卧胸板的剂量效应。